Evidence map›Paper›PMID 26579435›Full record

ReviewActa pharmaceutica Sinica. B2015

Epigenetic regulation of drug metabolism and transport.

Lai Peng, Xiaobo Zhong

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Acta pharmaceutica Sinica. B, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 92 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Costs of molecular adaptation to the chemical exposome: a focus on xenobiotic metabolism pathways.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2024
    Review
  12. Article
  13. Novel Approaches to Characterize Individual Drug Metabolism and Advance Precision Medicine.Drug metabolism and disposition: the biological fate of chemicals · 2023
    Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 3 countries.

Lai PengDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Connecticut, Storrs, CT 06269, USA ; Key Laboratory of System Biomedicine, Center for Comparative Biomedicine, Institute of Systems Biomedicine, Shanghai Jiao Tong University, Shanghai 200240, China.
Xiaobo ZhongDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Connecticut, Storrs, CT 06269, USA.
University of Connecticut · US

Funding

Developmental Regulation of Drug Processing GenesR01ES019487 · NIEHS · UNIVERSITY OF WASHINGTON · PI CUI, JULIA YUE, LU, HONG · 2010 to 2014
$3.0M
Control of developmental switch of Cyp3a gene expression in mouse liverR01GM087376 · NIGMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI ZHONG, XIAO-BO · 2010 to 2014
$1.5M
NIEHS NIH HHS R01 ES019487NIGMS NIH HHS R01 GM087376
6 · The paper itself

Abstract

The drug metabolism is a biochemical process on modification of pharmaceutical substances through specialized enzymatic systems. Changes in the expression of drug-metabolizing enzyme genes can affect drug metabolism. Recently, epigenetic regulation of drug-metabolizing enzyme genes has emerged as an important mechanism. Epigenetic regulation refers to heritable factors of genomic modifications that do not involve changes in DNA sequence. Examples of such modifications include DNA methylation, histone modifications, and non-coding RNAs. This review examines the widespread effect of epigenetic regulations on genes involved in drug metabolism, and also suggests a network perspective of epigenetic regulation. The epigenetic mechanisms have important clinical implications and may provide insights into effective drug development and improve safety of drug therapy.

Indexed as

CAR, constitutive androstane receptorDNA methylationDNMTs, DNA methyltransferasesDrug metabolismEpigeneticsH3K27me3, histone 3 lysine 27 trimethylationH3K36me3, histone 3 lysine 36 trimethylationH3K4me1, histone 3 lysine 4 monomethylationH3K4me2, histone 3 lysine 4 dimethylationH3K4me3, histone 3 lysine 4 trimethylationH3K9me2, histone 3 lysine 9 dimethylationH3K9me3, histone 3 lysine 9 trimethylationHATs, histone acetyltransferasesHDAC, histone deacetylasesHistone modificationlncRNAs, long non-coding RNAsmiRNAs, microRNAsncRNAs, non-coding RNAsNon-coding RNAP450s, cytochrome P450sSULTs, sulfotransferasesTransporterTSS, transcription start sitesUGTs, UDP-glucuronosyltransferasesUTR, untranslated region

Identifiers

PMID26579435
PMCPMC4629221
OpenAlexW2049179855

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.